Aminologics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Aminologics makes active pharmaceutical ingredients, the raw chemical substances that finished-drug manufacturers use to produce medicines, covering areas such as stroke treatment, eye disease, skin conditions, and cosmetics.
It also manufactures and supplies amino acid derivative compounds. The company supplies these ingredients to domestic Korean pharmaceutical companies that produce finished drugs, placing it upstream in the Korean drug supply chain. Aminologics is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
The Korean pharmaceutical industry is heavily regulated by the government at every stage, from approval and pricing to manufacturing, distribution, and supply, which shapes the operating environment for all domestic ingredient suppliers.
Aminologics in five facts
What does Aminologics do?
Aminologics makes active pharmaceutical ingredients, the raw chemical substances that finished-drug manufacturers use to produce medicines, covering areas such as stroke treatment, eye disease, skin conditions, and cosmetics.
Where is Aminologics listed and in which sector?
Aminologics (Korean name: 아미노로직스) trades under KRX code 074430 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Aminologics?
Its market capitalisation was US$67M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Aminologics's latest annual revenue and operating profit?
For fiscal year 2025, Aminologics reported revenue of US$16.6M, operating profit of US$2.7M and net income of US$2.7M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 31.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 8
- Report on securities held by executives/major shareholdersOct 2
- Report on securities held by executives/major shareholdersOct 2
- Report on securities held by executives/major shareholdersOct 2
- Report on large shareholdings (5% rule) (standard)Oct 2
- Report on securities held by executives/major shareholdersSep 16
- Report on securities held by executives/major shareholdersSep 16
- Report on securities held by executives/major shareholdersSep 16
- Report on large shareholdings (5% rule) (standard)Sep 16
- [Amended] DisclosureSep 15
- Material event reportCapital raise · Sep 11
- Material event report (CB call option holder designated)Capital raise · Sep 11
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Aminologics updated its previously filed consolidated results for FY2025: revenue of US$14.9M (+31.1% year on year), operating profit of US$2.43M (from a loss a year earlier) and net income of US$2.38M (from a loss a year earlier).
Earnings · Mar 6 · 2 versions